Cabaletta Bio Takes Autoimmune Cell Therapy Pitch to Investors
PHILADELPHIA, PA — Cabaletta Bio Inc. (Nasdaq: CABA) will meet with investors at four healthcare conferences in September, putting its late-stage autoimmune cell therapy program before the market as the …
Cabaletta Bio Takes Autoimmune Cell Therapy Pitch to Investors Read More